AKEBIA THERAPEUTICS, INC. Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross
AKEBIA THERAPEUTICS, INC. (AKBA) reported Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross of $75.90 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross · last filed 2026-08-05
- AKEBIA THERAPEUTICS, INC. research and development arrangement, contract to perform for others, costs incurred, gross for the quarter ending 2026-06-30 was -$5.60M, a 136.13% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. research and development arrangement, contract to perform for others, costs incurred, gross for the quarter ending 2026-03-31 was $81.50M, a 93.13% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. research and development arrangement, contract to perform for others, costs incurred, gross for the quarter ending 2025-12-31 was -$4.20M, a 520.00% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. research and development arrangement, contract to perform for others, costs incurred, gross for the quarter ending 2025-09-30 was $29.10M, a 9600.00% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. research and development arrangement, contract to perform for others, costs incurred, gross for fiscal 2025 was $82.60M, a 72.08% increase from fiscal 2024.
- AKEBIA THERAPEUTICS, INC. research and development arrangement, contract to perform for others, costs incurred, gross for fiscal 2024 was $48.00M, a 7.38% increase from fiscal 2023.
- AKEBIA THERAPEUTICS, INC. research and development arrangement, contract to perform for others, costs incurred, gross for fiscal 2023 was $44.70M, a 50.44% decline from fiscal 2022.
- AKEBIA THERAPEUTICS, INC. research and development arrangement, contract to perform for others, costs incurred, gross for fiscal 2022 was $90.20M, a 62.07% decline from fiscal 2021.
| Period end | Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross 3 month | Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross 6 month | Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross 9 month | Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross 12 month | Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$5.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $75.90M 10-Q · filed 2026-08-05 | $71.70M derived: sum of 3 quarters · filed 2026-08-05 | $100.80M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $81.50M 10-Q · filed 2026-05-07 | $77.30M derived: sum of 2 quarters · filed 2026-05-07 | $106.40M derived: sum of 3 quarters · filed 2026-05-07 | $121.90M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2025-12-31 | -$4.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $24.90M derived: sum of 2 quarters · filed 2026-02-26 | $40.40M derived: sum of 3 quarters · filed 2026-02-26 | $82.60M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $29.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $44.60M derived: sum of 2 quarters · filed 2025-11-10 | $86.80M 10-Q · filed 2025-11-10 | $87.80M derived: sum of 4 quarters · filed 2025-11-10 | |
| 2025-06-30 | $15.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $57.70M 10-Q · filed 2025-08-07 | $58.70M derived: sum of 3 quarters · filed 2025-08-07 | $59.00M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2025-03-31 | $42.20M 10-Q · filed 2025-05-08 | $43.20M derived: sum of 2 quarters · filed 2025-05-08 | $43.50M derived: sum of 3 quarters · filed 2025-05-08 | $42.30M derived: sum of 4 quarters · filed 2025-05-08 | |
| 2024-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $1.30M derived: sum of 2 quarters · filed 2025-03-13 | $100.00K derived: sum of 3 quarters · filed 2025-03-13 | $48.00M 10-K · filed 2025-03-13 | |
| 2024-09-30 | $300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$900.00K derived: sum of 2 quarters · filed 2024-11-07 | $47.00M 10-Q · filed 2024-11-07 | $46.30M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2024-06-30 | -$1.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $46.70M 10-Q · filed 2024-08-08 | $46.00M derived: sum of 3 quarters · filed 2024-08-08 | $36.50M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2024-03-31 | $47.90M 10-Q · filed 2024-05-09 | $47.20M derived: sum of 2 quarters · filed 2024-05-09 | $37.70M derived: sum of 3 quarters · filed 2024-05-09 | $15.00M derived: sum of 4 quarters · filed 2024-05-09 | |
| 2023-12-31 | -$700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$10.20M derived: sum of 2 quarters · filed 2024-03-14 | -$32.90M derived: sum of 3 quarters · filed 2024-03-14 | $44.70M 10-K · filed 2024-03-14 | |
| 2023-09-30 | -$9.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$32.20M derived: sum of 2 quarters · filed 2023-11-08 | $45.40M 10-Q · filed 2023-11-08 | -$40.70M derived: sum of 4 quarters · filed 2023-11-08 | |
| 2023-06-30 | -$22.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-28 | $54.90M 10-Q · filed 2023-08-28 | -$31.20M derived: sum of 3 quarters · filed 2023-08-28 | -$30.60M derived: sum of 4 quarters · filed 2023-08-28 | |
| 2023-03-31 | $77.60M 10-Q · filed 2023-05-08 | -$8.50M derived: sum of 2 quarters · filed 2023-08-28 | -$7.90M derived: sum of 3 quarters · filed 2023-08-28 | -$44.10M derived: sum of 4 quarters · filed 2023-08-28 | |
| 2022-12-31 | -$86.10M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28 | -$85.50M derived: sum of 2 quarters · filed 2023-08-28 | -$121.70M derived: sum of 3 quarters · filed 2023-08-28 | $90.20M 10-K/A · filed 2023-08-28 | |
| 2022-09-30 | $600.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$35.60M derived: sum of 2 quarters · filed 2022-11-03 | $176.30M 10-Q · filed 2022-11-03 | $169.70M derived: sum of 4 quarters · filed 2022-11-03 | |
| 2022-06-30 | -$36.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $175.70M 10-Q · filed 2022-08-04 | $169.10M derived: sum of 3 quarters · filed 2022-08-04 | $225.90M derived: sum of 4 quarters · filed 2022-08-04 | |
| 2022-03-31 | $211.90M 10-Q · filed 2022-05-09 | $205.30M derived: sum of 2 quarters · filed 2022-05-09 | $262.10M derived: sum of 3 quarters · filed 2022-05-09 | $257.40M derived: sum of 4 quarters · filed 2022-05-09 | |
| 2021-12-31 | -$6.60M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $50.20M derived: sum of 2 quarters · filed 2022-03-01 | $45.50M derived: sum of 3 quarters · filed 2022-03-01 | $237.80M 10-K · filed 2022-03-01 | |
| 2021-09-30 | $56.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $52.10M derived: sum of 2 quarters · filed 2021-11-04 | $244.40M 10-Q · filed 2021-11-04 | $280.50M derived: sum of 4 quarters · filed 2021-11-04 | |
| 2021-06-30 | -$4.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $187.60M 10-Q · filed 2021-08-05 | $223.70M derived: sum of 3 quarters · filed 2021-08-05 | $275.40M derived: sum of 4 quarters · filed 2021-08-05 | |
| 2021-03-31 | $192.30M 10-Q · filed 2021-05-10 | $228.40M derived: sum of 2 quarters · filed 2021-05-10 | $280.10M derived: sum of 3 quarters · filed 2021-05-10 | $280.80M derived: sum of 4 quarters · filed 2021-05-10 | |
| 2020-12-31 | $36.10M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $87.80M derived: sum of 2 quarters · filed 2021-02-25 | $88.50M derived: sum of 3 quarters · filed 2021-02-25 | $155.90M 10-K · filed 2021-02-25 | |
| 2020-09-30 | $51.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $52.40M derived: sum of 2 quarters · filed 2020-11-05 | $119.80M 10-Q · filed 2020-11-05 | $128.50M derived: sum of 4 quarters · filed 2020-11-05 | |
| 2020-06-30 | $700.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $68.10M 10-Q · filed 2020-08-10 | $76.80M derived: sum of 3 quarters · filed 2020-08-10 | $74.00M derived: sum of 4 quarters · filed 2020-08-10 | |
| 2020-03-31 | $67.40M 10-Q · filed 2020-05-05 | $76.10M derived: sum of 2 quarters · filed 2020-05-05 | $73.30M derived: sum of 3 quarters · filed 2020-05-05 | $56.90M derived: sum of 4 quarters · filed 2020-05-05 | |
| 2019-12-31 | $8.70M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $5.90M derived: sum of 2 quarters · filed 2020-03-12 | -$10.50M derived: sum of 3 quarters · filed 2020-03-12 | $61.40M 10-K · filed 2020-03-12 | |
| 2019-09-30 | -$2.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$19.20M derived: sum of 2 quarters · filed 2019-11-12 | $52.70M 10-Q · filed 2019-11-12 | $45.10M derived: sum of 4 quarters · filed 2019-11-12 | |
| 2019-06-30 | -$16.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $55.50M 10-Q · filed 2019-08-08 | $47.90M derived: sum of 3 quarters · filed 2019-08-08 | $52.00M derived: sum of 4 quarters · filed 2019-08-08 | |
| 2019-03-31 | $71.90M 10-Q · filed 2019-05-09 | $64.30M derived: sum of 2 quarters · filed 2019-05-09 | $68.40M derived: sum of 3 quarters · filed 2019-05-09 | $123.30M derived: sum of 4 quarters · filed 2019-05-09 | |
| 2018-12-31 | -$7.60M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | -$3.50M derived: sum of 2 quarters · filed 2019-03-26 | $51.40M derived: sum of 3 quarters · filed 2019-03-26 | $102.80M 10-K · filed 2019-03-26 | |
| 2018-09-30 | $4.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $59.00M derived: sum of 2 quarters · filed 2018-11-08 | $110.40M 10-Q · filed 2018-11-08 | $119.00M derived: sum of 4 quarters · filed 2018-11-08 | |
| 2018-06-30 | $54.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $106.30M 10-Q · filed 2018-08-08 | $114.90M derived: sum of 3 quarters · filed 2018-08-08 | $132.20M derived: sum of 4 quarters · filed 2018-08-08 | |
| 2018-03-31 | $51.40M 10-Q · filed 2018-05-09 | $60.00M derived: sum of 2 quarters · filed 2018-05-09 | $77.30M derived: sum of 3 quarters · filed 2018-05-09 | $83.20M derived: sum of 4 quarters · filed 2018-05-09 | |
| 2017-12-31 | $8.60M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $25.90M derived: sum of 2 quarters · filed 2018-03-12 | $31.80M derived: sum of 3 quarters · filed 2018-03-12 | $52.40M 10-K · filed 2018-03-12 | |
| 2017-09-30 | $17.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $23.20M derived: sum of 2 quarters · filed 2017-11-08 | $43.80M 10-Q · filed 2017-11-08 | $46.70M derived: sum of 4 quarters · filed 2017-11-08 | |
| 2017-06-30 | $5.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $26.50M 10-Q · filed 2017-08-08 | $29.40M derived: sum of 3 quarters · filed 2017-11-08 | $37.50M derived: sum of 4 quarters · filed 2017-11-08 | |
| 2017-03-31 | $20.60M 10-Q · filed 2017-05-09 | $23.50M derived: sum of 2 quarters · filed 2017-11-08 | $31.60M derived: sum of 3 quarters · filed 2017-11-08 | $31.80M derived: sum of 4 quarters · filed 2017-11-08 | |
| 2016-12-31 | $2.90M derived: 10-Q 12 month − 10-Q 9 month · filed 2017-11-08 | $11.00M derived: sum of 2 quarters · filed 2017-11-08 | $11.20M derived: sum of 3 quarters · filed 2017-11-08 | $24.90M 10-Q · filed 2017-11-08 | |
| 2016-09-30 | $8.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $8.30M derived: sum of 2 quarters · filed 2016-11-09 | $22.00M 10-Q · filed 2016-11-09 | $7.60M derived: sum of 4 quarters · filed 2016-11-09 | |
| 2016-06-30 | $200.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $13.90M 10-Q · filed 2016-08-08 | -$500.00K derived: sum of 3 quarters · filed 2016-11-09 | $9.90M derived: sum of 4 quarters · filed 2016-11-09 | |
| 2016-03-31 | $13.70M 10-Q · filed 2016-05-05 | -$700.00K derived: sum of 2 quarters · filed 2016-11-09 | $9.70M derived: sum of 3 quarters · filed 2016-11-09 | $12.34M derived: sum of 4 quarters · filed 2016-11-09 | |
| 2015-12-31 | -$14.40M derived: 10-Q 12 month − 10-Q 9 month · filed 2016-11-09 | -$4.00M derived: sum of 2 quarters · filed 2016-11-09 | -$1.36M derived: sum of 3 quarters · filed 2016-11-09 | $5.20M 10-Q · filed 2016-11-09 | |
| 2015-09-30 | $10.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $13.04M derived: sum of 2 quarters · filed 2015-11-09 | $19.60M 10-Q · filed 2015-11-09 | $17.27M derived: sum of 4 quarters · filed 2016-03-14 | |
| 2015-06-30 | $2.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-11 | $9.20M 10-Q · filed 2015-08-11 | $6.87M derived: sum of 3 quarters · filed 2016-03-14 | $5.34M derived: sum of 4 quarters · filed 2016-03-14 | |
| 2015-03-31 | $6.56M 10-Q · filed 2015-05-11 | $4.24M derived: sum of 2 quarters · filed 2016-03-14 | $2.71M derived: sum of 3 quarters · filed 2016-03-14 | $6.83M derived: sum of 4 quarters · filed 2016-03-14 | |
| 2014-12-31 | -$2.33M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | -$3.86M derived: sum of 2 quarters · filed 2016-03-14 | $267.63K derived: sum of 3 quarters · filed 2016-03-14 | $4.30M 10-K · filed 2016-03-14 | $4.31M 10-K · filed 2015-03-04 |
| 2014-09-30 | -$1.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $2.60M derived: sum of 2 quarters · filed 2014-11-10 | $6.63M 10-Q · filed 2014-11-10 | ||
| 2014-06-30 | $4.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $8.16M 10-Q · filed 2014-08-11 | |||
| 2014-03-31 | $4.03M 10-Q · filed 2014-05-12 | ||||
| 2013-12-31 | $4.48M 10-K · filed 2015-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |